Article
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms.
Experimental hematology - 1 Mar 2022
Van Egeren Debra, Kamaz Baransel, Liu Shichen, Nguyen Maximilian, Reilly Christopher R, Kalyva Maria, DeAngelo Daniel J, Galinsky Ilene, Wadleigh Martha, Winer Eric S, Luskin Marlise R, Stone Richard M, Garcia Jacqueline S, Hobbs Gabriela S, Michor Franziska, Cortes-Ciriano Isidro, Mullally Ann, Hormoz Sahand
Abstract excerpt
The JAK2-V617F mutation is the most common cause of myeloproliferative neoplasms. Although experiments have revealed that this gain-of-function mutation is associated with myeloid blood cell expansion and increased production of white cells, red cells, and platelets, the transcriptional consequences of the JAK2-V617F mutation in different cellular compartments of the bone marrow have not yet been fully...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.